Expand MIRM Menu
MIRM MENU

MIRM Latest Press Releases

-- February 10, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 10:45 PM

-- February 5, 2026 --

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Business Wire 8:51 AM
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) Business Wire 8:00 AM

-- January 26, 2026 --

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease Business Wire 8:00 AM

-- January 12, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:30 PM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum Business Wire 8:30 AM

-- January 9, 2026 --

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals Business Wire 11:55 AM

-- January 7, 2026 --

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:01 PM

-- December 19, 2025 --

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX Business Wire 8:30 AM

-- December 10, 2025 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 PM

-- December 8, 2025 --

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease Business Wire 8:00 AM

-- December 1, 2025 --

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome Business Wire 8:10 AM

-- November 25, 2025 --

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 4:02 PM

-- November 10, 2025 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 8:00 PM

-- November 7, 2025 --

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting Business Wire 8:10 AM

-- November 4, 2025 --

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire 4:01 PM

-- November 3, 2025 --

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- October 28, 2025 --

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 Business Wire 4:02 PM

-- October 10, 2025 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:45 PM
Market Data Delayed 15 Minutes